Draft Provider-Administered Drug Policies (Excluding Oncology) - Blue Advantage

To ensure that the development of Blue Cross and Blue Shield of Alabama provider-administered policies occurs through an open, collaborative process, we welcome physicians and other providers to submit comments about pharmacy policies that are in the draft stage.

Note: Coverage is subject to member's specific benefits. Group-specific policies will supersede these policies when applicable. Please refer to member's benefit plan.

Current Draft Policies

Draft provider-administered drug policies (excluding oncology) are listed below in alphabetical order. If there are no policies listed, then no policies are in draft status.

How to Submit Comments

We invite our participating physicians and other providers to submit scientific, evidence-based information, professional consensus opinions and other information supported by medical literature relevant to these draft policies for consideration. We receive comments for 45 days from the posting date listed on the document.

Participating providers can comment on draft policies two ways:

  1. Comment on Draft Pharmacy Policy
  2. Send comments by fax to 205-733-6471 using the Drug Policy Comments Coversheet




Policy # Policy Title Print View
PH-90347 Fasenra (benralizumab)